{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:45:31Z","timestamp":1793094331339,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jaip.2024.05.045","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T13:03:47Z","timestamp":1717765427000},"page":"2798-2808.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["First-Line Antituberculosis Drug Challenge Reactions in Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in an HIV Endemic Setting"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4507-6995","authenticated-orcid":false,"given":"Mireille","family":"Porter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhodine","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bukiwe","family":"Thwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuti","family":"Choshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sipho","family":"Dlamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Grant","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1281-1789","authenticated-orcid":false,"given":"Rannakoe J.","family":"Lehloenya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2024.05.045_bib2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/ACI.0000000000000545","article-title":"Drug hypersensitivity in HIV infection","volume":"19","author":"Peter","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.05.045_bib4","series-title":"Global tuberculosis report, 2020","year":"2020"},{"key":"10.1016\/j.jaip.2024.05.045_bib5","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.jaip.2020.07.005","article-title":"Delabeling delayed drug hypersensitivity: how far can you safely go?","volume":"8","author":"Lehloenya","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.05.045_bib6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199306103282304","article-title":"Cutaneous disease and drug reactions in HIV infection","volume":"328","author":"Coopman","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.05.045_bib7","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.5588\/ijtld.10.0698","article-title":"Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions","volume":"15","author":"Lehloenya","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jaip.2024.05.045_bib8","series-title":"The First National TB Prevalence Survey\u2014South Africa 2018. 2021","year":"2021"},{"key":"10.1016\/j.jaip.2024.05.045_bib9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1586\/eri.12.13","article-title":"Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future","volume":"10","author":"Lehloenya","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jaip.2024.05.045_bib10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1258\/ijsa.2008.008361","article-title":"Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs","volume":"20","author":"Marks","year":"2009","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.jaip.2024.05.045_bib11","article-title":"Long-term HIV and tuberculosis outcomes in patients hospitalised with severe cutaneous adverse reactions","volume":"32","author":"Veenstra","year":"2023","journal-title":"J\u00a0Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.jaip.2024.05.045_bib12","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/tmi.13275","article-title":"Cost of managing severe cutaneous adverse drug reactions to first-line tuberculosis therapy in South Africa","volume":"24","author":"Knight","year":"2019","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.jaip.2024.05.045_bib13","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/archinte.163.9.1009","article-title":"The growing burden of tuberculosis: global trends and interactions with the HIV epidemic","volume":"163","author":"Corbett","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaip.2024.05.045_bib14","doi-asserted-by":"crossref","unstructured":"Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: second report: Third East African\/British Medical Research Council: study. Tubercle 1980;61:59-69.","DOI":"10.1016\/0041-3879(80)90012-4"},{"key":"10.1016\/j.jaip.2024.05.045_bib15","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(19)30154-7","article-title":"Management of active tuberculosis in adults with HIV","volume":"6","author":"Meintjes","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jaip.2024.05.045_bib16","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/thx.53.7.536","article-title":"Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society","volume":"53","year":"1998","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2024.05.045_bib17","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1183\/09031936.96.09102026","article-title":"Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis","volume":"9","author":"Schaberg","year":"1996","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.05.045_bib18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/bjd.14839","article-title":"Drug-specific CD4(+) T-cell immune responses are responsible for antituberculosis drug-induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome","volume":"176","author":"Ye","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2024.05.045_bib19","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1016\/j.jid.2022.05.1059","article-title":"IFN-\u03b3 ELISpot in severe cutaneous adverse reactions to first-line antituberculosis drugs in an HIV endemic setting","volume":"142","author":"Porter","year":"2022","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2024.05.045_bib20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamadermatol.2013.6698","article-title":"Prolonged evolution of drug reaction with eosinophilia and systemic symptoms: clinical, virologic, and biological features","volume":"150","author":"Tetart","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2024.05.045_bib21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/jdv.12419","article-title":"Recurrence of drug-induced reactions in DRESS patients","volume":"29","author":"Picard","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2024.05.045_bib22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaad.2014.10.032","article-title":"Therapeutic management of DRESS: a retrospective study of 38 cases","volume":"72","author":"Funck-Brentano","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.05.045_bib23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.det.2013.11.004","article-title":"Clinical presentations of severe cutaneous drug reactions in HIV-infected Africans","volume":"32","author":"Lehloenya","year":"2014","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaip.2024.05.045_bib25","first-page":"270","article-title":"A\u00a0South African multi-disciplinary drug hypersensitivity clinic","volume":"28","author":"Peter","year":"2015","journal-title":"Curr Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.05.045_bib26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2024.05.045_bib27","doi-asserted-by":"crossref","first-page":"1000.e2","DOI":"10.1016\/j.jaad.2013.11.053","article-title":"Comments on: DRESS syndrome","volume":"71","author":"Kardaun","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2024.05.045_bib28","series-title":"Common Terminology Criteria for Adverse Events (CTCAE), 2017.","year":"2017"},{"key":"10.1016\/j.jaip.2024.05.045_bib29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A\u00a0method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2024.05.045_bib30","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaip.2020.08.012","article-title":"Early high-dose intravenous corticosteroids rapidly arrest Stevens Johnson syndrome and drug reaction with eosinophilia and systemic symptoms recurrence on drug re-exposure","volume":"9","author":"Lehloenya","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.05.045_bib31","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaip.2019.06.009","article-title":"Multiple drug hypersensitivity syndrome in a large database","volume":"8","author":"Landry","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.05.045_bib32","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/jac\/dkv158","article-title":"Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases","volume":"70","author":"Lehloenya","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jaip.2024.05.045_bib33","unstructured":"StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LLC;\u00a02015."},{"key":"10.1016\/j.jaip.2024.05.045_bib34","article-title":"An updated review of the diagnostic methods in delayed drug hypersensitivity","volume":"11","author":"Copaescu","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2024.05.045_bib35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/icb.2011.34","article-title":"High-avidity, high-IFN\u03b3-producing CD8 T-cell responses following immune selection during HIV-1 infection","volume":"90","author":"Keane","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jaip.2024.05.045_bib36","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.5588\/ijtld.11.0187","article-title":"Multiple drug hypersensitivity reactions to anti-tuberculosis drugs: five cases in HIV-infected patients","volume":"16","author":"Lehloenya","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jaip.2024.05.045_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw130","article-title":"Therapeutic trial of rifabutin after rifampicin-associated DRESS syndrome in tuberculosis-human immunodeficiency virus coinfected patients","volume":"3","author":"Lehloenya","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jaip.2024.05.045_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2019.103937","article-title":"Evolution of rifampicin treatment for tuberculosis","volume":"74","author":"Grobbelaar","year":"2019","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.jaip.2024.05.045_bib39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000496389","article-title":"An update on adverse cutaneous drug reactions in HIV\/AIDS","volume":"6","author":"Hoosen","year":"2019","journal-title":"Dermatopathology (Basel)"},{"key":"10.1016\/j.jaip.2024.05.045_bib40","first-page":"237","article-title":"Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report","volume":"2","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2024.05.045_bib41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.rmed.2018.12.017","article-title":"Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications","volume":"147","author":"Ban","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2024.05.045_bib42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaci.2018.02.018","article-title":"Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes","volume":"142","author":"Isabwe","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.05.045_bib43","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jaip.2020.08.006","article-title":"Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs","volume":"8","author":"Broyles","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.05.045_bib44","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12016-021-08877-y","article-title":"Hypersensitivity reactions to platinum agents and taxanes","volume":"62","author":"Tsao","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2024.05.045_bib45","article-title":"Medical diagnosis reimagined as a process of Bayesian reasoning and elimination","volume":"15","author":"Ananda Rao","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2024.05.045_bib46","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jaci.2023.08.018","article-title":"United States Drug Allergy Registry (USDAR) grading scale for immediate drug reactions","volume":"152","author":"Khan","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.05.045_bib47","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000458725","article-title":"Multiple drug hypersensitivity","volume":"172","author":"Pichler","year":"2017","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2024.05.045_bib48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13601-020-00359-2","article-title":"Drug-related relapses in drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"10","author":"J\u00f6rg","year":"2020","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2024.05.045_bib49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11882-001-0092-5","article-title":"Multiple drug allergy syndrome: a distinct clinical entity","volume":"1","author":"Asero","year":"2001","journal-title":"Curr Allergy Rep"},{"key":"10.1016\/j.jaip.2024.05.045_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2022.12.364","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) with dual sensitization to both vancomycin and ceftriaxone","volume":"151","author":"Krantz","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.05.045_bib51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00403-023-02741-z","article-title":"Flares in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms: a retrospective study","volume":"316","author":"Yang","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaip.2024.05.045_bib52","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.jaip.2018.11.041","article-title":"Treatment can be continued for mild cutaneous reactions associated with efavirenz","volume":"7","author":"Isaacs","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.05.045_bib53","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/ACI.0b013e3283630c36","article-title":"Multiple drug hypersensitivity syndrome","volume":"13","author":"Chiriac","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.05.045_bib54","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaip.2020.08.012","article-title":"Early high-dose intravenous corticosteroids rapidly arrest Stevens Johnson syndrome and drug reaction with eosinophilia and systemic symptoms recurrence on drug re-exposure","volume":"9","author":"Lehloenya","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824005762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824005762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T05:45:42Z","timestamp":1728279942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219824005762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2213219824005762"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2024.05.045","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-Line Antituberculosis Drug Challenge Reactions in Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in an HIV Endemic Setting","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2024.05.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}